Cytokines and Pentraxin 3 Levels in Unexplained Recurrent Pregnancy Loss: Role of Oral Micronized Progesterone Therapy as Immunomodulator on Their Levels and Pregnancy Outcome, a Prospective Comparative Study
- 19 February 2024
- journal article
- research article
- Published by Springer Nature in The Journal of Obstetrics and Gynecology of India
- Vol. 75 (1) , 59-66
Abstract
Objective To assess cytokines(TNFα, IL6) and pentraxin3(PTX3) in unexplained recurrent pregnancy loss(RPL) compared to controls and to evaluate immunomodulatory effect of oral micronized progesterone. Methods This prospective comparative trial was conducted in 90 pregnant females: 60 RPL(group-1) and 30 controls(group-2). Group-1 was randomized into group-1a (n = 30) receiving oral micronized progesterone 200 mg twice daily and group-1b (n = 30) not receiving progesterone. TNFα(Th1-cytokine), IL6(Th2-cytokine) and PTX3 were measured at baseline(< 8 weeks), 16 weeks and at abortion/delivery. Results In all three groups, baseline TNFα, IL6 and PTX3 were similar; and levels increased as pregnancy advanced. However, progesterone modulated the rise favorably in group-1a, which was similar to controls (group-2). A significant rise at 16 weeks was noted for TNFα in group-1b (p = 0.0002); IL6 in group-1a (p = 0.0001) and group-2 (p = 0.04); and PTx3 in group-1b (p = 0.028); number of previous abortions not affecting rise. The abortion rate was 3.5% vs. 16.7% in group-1a and 1b, respectively. No patient aborted if baseline TNFα was < 6.5 pg/ml and PTx3 was < 3441 pg/ml. Conclusion Favorable shift in TNFα, IL6 and PTx3 levels with oral micronized progesterone appears to exert immunomodulatory effect that support pregnancy continuation in RPL. Baseline TNFα < 6.5 pg/ml and PTx3 < 3441 pg/ml have good pregnancy outcome even without progesterone support. Women with higher levels than these can be offered progesterone therapy. Trial registration Clinical trial registry of India (CTRI/2016/09/007278).Keywords
Funding Information
- All-India Institute of Medical Sciences, New Delhi
This publication has 18 references indexed in Scilit:
- Cytokine imbalance at materno-embryonic interface as a potential immune mechanism for recurrent pregnancy lossInternational Immunopharmacology, 2021
- Effects of Progesterone, Dydrogesterone and Estrogen on the Production of Th1/Th2/Th17 Cytokines by Lymphocytes from Women with Recurrent Spontaneous MiscarriageJournal of Reproductive Immunology, 2020
- Peripheral Gamma Delta T cells secrete inflammatory cytokines in women with idiopathic recurrent pregnancy lossCytokine, 2018
- RETRACTED: Oral dydrogesterone treatment during early pregnancy to prevent recurrent pregnancy loss and its role in modulation of cytokine production: a double-blind, randomized, parallel, placebo-controlled trialFertility and Sterility, 2014
- First trimester assessment of Pentraxin-3 levels in women with primary unexplained recurrent pregnancy lossEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 2012
- Pentraxin 3 Values During Normal PregnancyInflammation, 2010
- Diagnostic factors identified in 1020 women with two versus three or more recurrent pregnancy lossesFertility and Sterility, 2010
- Progesterone-induced blocking factor (PIBF) modulates cytokine production by lymphocytes from women with recurrent miscarriage or preterm deliveryJournal of Reproductive Immunology, 2009
- Cytokines in recurrent pregnancy lossJournal of Reproductive Immunology, 2004
- Lack of association of TNFα gene polymorphisms and recurrent pregnancy loss in Caucasian womenJournal of Reproductive Immunology, 2004